Hope S. Rugo, MD

Articles

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer

July 19th 2024

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Stephanie L. Graff, MD, FACP;Reshma L. Mahtani, DO;Kelly E. McCann, MD, PhD;Hope S. Rugo, MD

April 11th 2024

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Hope Rugo, MD, an expert on breast cancer, presenting slides

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

Hope S. Rugo, MD

November 28th 2023

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Sacituzumab Govitecan vs Treatment of Physician’s Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients with HR+/HER2– Metastatic Breast Cancer

Hope S. Rugo, MD

January 10th 2023

Hope Rugo, MD discusses key data updates on the TROPiCS-02 study on sacituzumab govitecan in patients with endocrine-resistant, HR+/HER2- advanced breast cancer that were recently presented at the 2022 San Antonio Breast Cancer Symposium.

Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer

Hope S. Rugo, MD

October 18th 2022

Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.

Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

Caroline Seymour;Hope S. Rugo, MD

September 10th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Optimizing Management of HR+/HER2- BC: Future Directions in Care

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri, MD, FACP;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

Hope S. Rugo, MD;Aditya Bardia, MD;Anne P. O’Dea, MD;Komal Jhaveri, MD;Mark D. Pegram, MD

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

Hope S. Rugo, MD;Aditya Bardia, MD;Komal Jhaveri, MD;Mark D. Pegram, MD;Anne P. O’Dea, MD

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

Hope S. Rugo, MD;Aditya Bardia, MD;Komal Jhaveri, MD;Mark D. Pegram, MD;Anne P. O’Dea, MD

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

Hope S. Rugo, MD;Aditya Bardia, MD;Komal Jhaveri, MD;Mark D. Pegram, MD;Anne P. O’Dea, MD

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

Novel Chemoprotective Therapies Under Investigation

Hope S. Rugo, MD;William J. Gradishar, MD

November 29th 2021

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies used to treat solid tumors.

CIN: Takeaways From the PROTECTIVE-1 Study

Hope S. Rugo, MD;Rita Nanda, MD, The University of Chicago Medicine;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;William J. Gradishar, MD, Northwestern University

November 12th 2021

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

CIN Treatment Advances: SIMBA Therapy

Hope S. Rugo, MD;William J. Gradishar, MD;Rita Nanda, MD, The University of Chicago Medicine

November 12th 2021

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.

Dr. Rugo on Overall Survival With First-Line Pembrolizumab in Metastatic TNBC

Hope S. Rugo, MD

September 19th 2021

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.